<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neuropsychopharmacology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuropsychopharmacology</journal-id>
<journal-title-group>
<journal-title>Neuropsychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-133X</issn>
<issn pub-type="epub">1740-634X</issn>
<publisher>
<publisher-name>Nature Publishing Group</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27654215</article-id>
<article-id pub-id-type="pmc">5143505</article-id>
<article-id pub-id-type="pii">npp2016211</article-id>
<article-id pub-id-type="doi">10.1038/npp.2016.211</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuropsychopharmacology Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions</article-title>
<alt-title alt-title-type="running">Schizophrenia immunophenotype</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Miller</surname>
<given-names>Brian J</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="corresp" rid="caf1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goldsmith</surname>
<given-names>David R</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<aff id="aff1"><label>1</label><institution>Department of Psychiatry and Health Behavior, Augusta University</institution>, Augusta, GA, <country>USA</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Psychiatry and Behavioral Sciences, Emory University</institution>, Atlanta, GA, <country>USA</country></aff>
</contrib-group>
<author-notes>
<corresp id="caf1"><label>*</label><institution>Department of Psychiatry and Health Behavior, Augusta University</institution>, 997 Saint Sebastian Way, Augusta, GA 30912, <country>USA</country>, Tel: +1-706-721-4445, Fax: +1-706-721-6602, E-mail: <email>brmiller@augusta.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>01</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epreprint">
<day>22</day>
<month>09</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>19</day>
<month>10</month>
<year>2016</year>
</pub-date>
<volume>42</volume>
<issue>1</issue>
<fpage>299</fpage>
<lpage>317</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>04</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>19</day>
<month>09</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>09</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright Â© 2017 American College of Neuropsychopharmacology</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>American College of Neuropsychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>The evidence to date, coupled with advances in immunology and genetics has afforded the field an unparalleled opportunity to investigate the hypothesis that a subset of patients with schizophrenia may manifest an immunophenotype, toward new potential diagnostics and therapeutics to reduce risk, alleviate symptoms, and improve quality of life in both at-risk populations and patients with established schizophrenia. In this paper, we will first summarize the findings on immune dysfunction in schizophrenia, including (1) genetic, prenatal, and premorbid immune risk factors and (2) immune markers across the clinical course of the disorder, including cytokines; C-reactive protein; immune cells; antibodies, autoantibodies and comorbid autoimmune disorders; complement; oxidative stress; imaging of neuroinflammation; infections; and clinical trials of anti-inflammatory agents and immunotherapy. We will then discuss a potential mechanistic framework toward increased understanding of a potential schizophrenia immunophenotype. We will then critically appraise the existing literature, and discuss suggestions for the future research agenda in this area that are needed to rigorously evaluate this hypothesis.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>